Details of the Drug

General Information of Drug (ID: DMRI010)

• Drug Name: Trastuzumab deruxtecan

Indication

Disease Entry	ICD 11	Status	REF
HER2-positive breast cancer	2C60-2C65	Approved	[1]
Colorectal cancer	2B91.Z	Phase 2	[2]

• Affected Organisms: Humans and other mammals
• ATC Code:
  L01FD04: Trastuzumab deruxtecan
  L01FD: HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
  L01F: MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
  L01: ANTINEOPLASTIC AGENTS
  L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
• Drug Type: Antibody drug conjugate
• Cross-matching ID:
  UNII: 5384HK7574
  DrugBank ID: DB14962
  TTD ID: D06BHB
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)